In a sec­ond big set­back for Covid-19 an­ti­body treat­ment hopes, Re­gen­eron halts en­roll­ment for more se­vere pa­tients

5 years ago
R&D
Coronavirus

Covid-19 roundup: Flush with $486M con­tract, As­traZeneca signs Lon­za up to man­u­fac­ture an­ti­bod­ies; BioN­Tech's Ugur ...

5 years ago
Coronavirus

In ear­ly blow to Ken­ji Ya­sukawa's R&D re­vamp, Astel­las drops out of the TIG­IT race, cit­ing PhI fail­ure

5 years ago
R&D

Trou­bled Unum re­brands as Co­gent Bio­sciences, re­places CEO Chuck Wil­son with An­drew Rob­bins; Jen­nifer Fox ap­point­ed ...

5 years ago
Peer Review

Two more biotechs price IPOs, bring­ing to­tal raise to record heights

5 years ago
Financing

Bel­licum slash­es 79% of staffers af­ter ear­ly da­ta quash hope around next-gen CAR-T

5 years ago
People
Cell/Gene Tx

No­vo Nordisk qui­et­ly nabs a rare 'break­through' sta­tus in NASH for its cash cow

5 years ago
Pharma
FDA+

George Golumbes­ki and Fa­heem Has­nain team up with Ver­tex Ven­tures HC in man­ag­ing $320M of biotech cash

5 years ago
People
Financing

A p-val­ue of 0.38? NE­JM re­sults raise new ques­tions for Eli Lil­ly's vaunt­ed Covid an­ti­body

5 years ago
R&D
Coronavirus

Flag­ship launch­es Sen­da Bio­sciences with $88M in back­ing, look­ing to pi­o­neer the field of 'In­ter­sys­tems Bi­ol­o­gy'

5 years ago
Financing
Startups

Q32 Bio grabs $60M to kick off hu­man stud­ies for next-gen com­ple­ment drugs — with some Covid-19 tweaks along the ...

5 years ago
Financing

GSK's Hal Bar­ron ax­es a once-prized drug from J&J, con­tin­u­ing shift away from res­pi­ra­to­ry

5 years ago
R&D

Per­cep­tive re­cruits A-list in­vestors to back its in-house Chi­na start­up with a mam­moth $310M raise

5 years ago
Financing
China

Ar­cus and As­traZeneca part­ner on a high stakes an­ti-TIG­IT/PD-L1 PhI­II can­cer study, look­ing to im­prove on a stan­dard ...

5 years ago
Deals

Covid-19 roundup: Mod­er­na posts $1.1B in Covid-19 vac­cine de­posits; Gilead CEO sees po­ten­tial need for Vek­lury on a ...

5 years ago
Coronavirus

Re­gen­eron posts sec­ond look on Covid-19 an­ti­body cock­tail, boost­ing its case for EUA — but what about symp­tom ...

5 years ago
R&D
Coronavirus

No­var­tis buys a new gene ther­a­py for vi­sion loss, and this is one pre­clin­i­cal ven­ture that did­n't come cheap

5 years ago
Deals
Cell/Gene Tx

Sanofi teams up with Mer­ck to pair Keytru­da with a next-gen IL-2 can­di­date from the Syn­thorx buy­out

5 years ago
Deals
Pharma

Gilead hits the brakes on a tri­fec­ta of mid- and late-stage stud­ies for their trou­bled fil­go­tinib pro­gram. It's up to ...

5 years ago
R&D

Eli Lil­ly part­ner TVM Cap­i­tal rais­es $478M for their new life sci­ences fund, a 'sub­stan­tial' over­sub­scrip­tion

5 years ago
Financing

A small buy­out deal gives a pen­ny-stock biotech a boost and a sec­ond chance

5 years ago
Financing

News brief­ing: Spring­Works, Jazz ex­change $35M and PTSD drug; Dr. Red­dy's says cy­ber­at­tack was ran­somware

5 years ago
News Briefing

For­mer Al­ler­gan pro­gram posts pos­i­tive topline PhI­II re­sults in pres­by­opia in an R&D win post-Ab­b­Vie merg­er

5 years ago
R&D

Bris­tol My­er­s' Richard Har­g­reaves pays $70M to launch a neu­rode­gen­er­a­tion al­liance with a star play­er in the ma­chine ...

5 years ago
Deals
AI
First page Previous page 783784785786787788789 Next page Last page
A service from the Financial Times